Outcome assessment of minimizing vancomycin monitoring and dosing adjustments

Pharmacotherapy

Volumn 19, Issue 3, 1999, Pages 257-266

  Karam, Christine M ^a,b   McKinnon, Peggy S ^a,b   Neuhauser, Melinda M ^a   Rybak, Michael J ^a,b,c  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b WSU   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ARTICLE; COST CONTROL; CREATININE CLEARANCE; DATA ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG MONITORING; ERADICATION THERAPY; INFECTION; PRACTICE GUIDELINE; TREATMENT OUTCOME;

EID: 0033016750     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.4.257.30933     Document Type: Article

References (41)

1. Geraci JE, Heilman DR, Nichols DR, Wellman WE. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis. Proc Staff Meet Mayo Clin 1958;33:172-81.
2. Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992;36:1766-9.
3. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995;15:85-91.
4. James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996;40:696-700.
5. Rybak MJ, Boike SC. Individualized adjustment of vancomycin dosage: comparison with two dosage nomograms. Drug Intell Clin Pharm 1986;20:64-8.
6. Brummett RE, Fox KE. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother 1989;33:791-6.
7. Dangerfield HG, Hewitt WL, Monzon OT, Kudinoff Z, Blackman B, Finegold SM. Clinical use of vancomycin. Antimicrob Agents Annu 1960;4:28-37.
8. Geraci JE. Vancomycin. Mayo Clin Proc 1977;52:631-4.
9. Cooper GL, Given DB, eds. Vancomycin adverse effects. In: Vancomycin: a comprehensive review of 30 years of clinical experience. Indianapolis, IN: Park Row Publishers, 1986:71
10. Farber BF, Moellering RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983;23:138-41.
11. Pestotnik SL, Classen DC, Lloyd JF, Burke JP. Adverse effects of intravenous vancomycin (IVV) in hospital patients: attributable costs and excess length of stay. Presented at the 35th annual meeting of the Infectious Diseases Society of America, San Francisco, Sept. 14, 1997.
12. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25:679-87.
13. Rybak MJ, Cappelletty DM, Ruffing MJ, et al. Influence of vancomycin serum concentrations on the outcome of patients being treated for gram-positive infections. Presented at the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario, Canada, Sept. 29 1997.
14. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987;83:1091-7.
15. Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 1990;10:378-82.
16. Wysocki M, Thomas F, Wolff MA, Pean Y, Ravaud Y, Herman B. Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections. J Antimicrob Chemother 1995;35:352-4.
17. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994;18:533-43.
18. Moellering RC. Pharmacokinetics of vancomycin. J Antimicrob Chemother 1984;14(suppl D):43-52.
19. Moellering RC. Monitoring serum vancomycin levels: climbing the mountain because it is there? [editorial]. Clin Infect Dis 1994;18:544-6.
20. Rodvold, KA, Zokufa H, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clin Pharm 1987;6:655-68.
21. Edwards DJ, Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting for the proof of its value. Clin Pharm 1987;6:652-4.
22. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993;27:594-8.
23. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet 1994;344:1748-50.
24. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994;16:513-18.
25. Lerner SA, Matz GJ, Schmitt BA, Seligsohn R. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin and gentamicin. AmJ Med 1986;80(suppl 6B):98-104.
26. Foran FM, Brett JL, Wulf PH. Evaluating the cost impact of intravenous antibiotic dosing frequencies. Ann Pharmacother 1991;25:546-52.
27. Foran FM, Brett JL, Wulf PH. Evaluating the cost impact of intravenous antibiotic dosing frequencies. Ann Pharmacother 1991;25:546-52.
28. Rybak MJ, Albreight LM, Berman JR, Warbasse LH, Svensson CR. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990;34:792-5.
29. Garaud JJ, Regnier B, Inglebert F, Faurisson F, Bauchet J, Vachon F. Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother 1984;14(suppl D):53-7.
30. Garrelts JC, Peterie JD. Altered vancomycin dose vs serum concentration relationship in burn patients. Clin Pharmacol Ther 1988;44:9-13.
31. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984;25:433-7.
32. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988;32:848-52.
33. Schaad, UB, McCracken GH, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980;96:119-26.
34. Boccazzi A, Langer M, Mandelli M, Ranzi AM, Urso R. The pharmacokinetics of aztreonam and penetration into the bronchial secretions of critically ill patients. J Antimicrob Chemother 1989;23:401-7.
35. Mann HJ, Townsend RJ, Fuhs DW, Cerra FB. Decreased hepatic clearance of clindamycin in critically ill patients with sepsis. Clin Pharm 1987;6:154-9.
36. Plaisance KI, Quintiliani R, Nightingale CH. The pharmacokinetics of metronidazole and its metabolites in critically ill patients. J Antimicrob Chemother 1988;21:195-200.
37. Yuen GJ, Drusano GL, Plaisance K, Forrest A, Caplan ES. Ciprofloxacin pharmacokinetics in critically ill trauma patients. Am J Med 1989;87(suppl 5A):70S-5.
38. Rybak MJ, Cappelletty DM, Kang SL, Levine DP, Levison ME. Pharmacodynamic evaluation of teicoplanin versus vancomycin in the treatment of gram-positive bacteremia and endocarditis. Presented at the 36th interscience conference on antimicrobial agents and chemotherapy, New Orleans, LA, Sept. 2, 1996.
39. Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985; 16:235-41.
40. Lake KD, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985;5:340-4.
41. Moellering RC, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981;94:343-6.